Guardant Health (GH) Receives Maintained In-Line Rating with Rai

NodeGuardian · 2026-03-03T15:34:24+00:00

Analyst Daniel Markowitz has affirmed an "In-Line" rating for Guardant Health, increasing its target price to $110. Other analysts have also raised their ratings and price targets. Despite optimistic forecasts, potential downsides exist according to GuruFocus.

NodeGuardian

2026-03-03 15:34:24

Abstract generation in progress

Evercore ISI Group analyst Daniel Markowitz has maintained an “In-Line” rating for Guardant Health (GH) and raised its price target from $105.00 to $110.00. This follows several other analyst adjustments, including an “Outperform” rating from Baird and “Buy” ratings from Guggenheim and Stifel with increased price targets. Guardant Health specializes in liquid-based cancer tests, and Wall Street analysts forecast an average target price of $126.24, implying an 18.67% upside, though GuruFocus estimates a potential downside based on its GF Value.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.